

miss. Recent data from our experience with the active CPT-11/oxaliplatin combination will be presented, as well as published or ongoing results of CPT-11/5-FU combinations and oxaliplatin/5-FU combinations. We are now in colorectal cancer treatment exactly where we were twenty years ago with breast cancer. We should not repeat time wasting errors, and try to take the opportunities without waiting for metaanalysis or consensus decisions making.

1297

Adjuvant therapy: how effective, and for which patients? A meta-analysis

Richard Gray. *University of Birmingham Trials Unit, Birmingham B15 2TA on behalf of the Colorectal Cancer collaborative Group, UK*

Chemotherapy can improve survival in colorectal cancer. To help define the size of benefit achievable for different types of patient, and the optimal chemotherapy regimen, a meta-analysis of all randomised trials comparing chemotherapy with surgery alone was undertaken. Individual patient data from a systematic overview of studies starting before 1987, was supplemented by published data from more recent studies. Almost all chemotherapy regimens tested involved 5-fluorouracil (5-FU), with or without other drugs. The 50 studies, involving 18,000 patients, were divided into broad groups based on pharmacokinetic considerations. As anticipated, short bolus chemotherapy regimens appeared the least effective. But, when 5-FU was given as a one-week continuous infusion through the portal vein the annual death rate was reduced by 14%SD5 ($p = 0.006$). Considering all prolonged systemic chemotherapy regimens together, the death rate was reduced by 11%SD3 ($p = 0.001$). However, the benefits seen in studies of 5-FU biomodulated by folinic acid (29%SD9; $p = 0.0007$) or by levamisole (22%SD9; $p = 0.01$) were significantly larger than in studies testing unmodulated 5-FU regimens (6%SD4; $p = 0.11$). There remain unanswered questions about who should be treated as most trials of 5-FU/folinic acid included only colon cancer patients and most of the benefit seen in them was among Dukes stage C (N+) patients. It seems reasonable to extrapolate from colon to rectal cancer as in the earlier trials of unmodulated 5-FU the benefits appeared similar for rectal and colon cancer. But, for stage B (N-) patients worthwhile benefit is not yet firmly established and more randomised evidence is needed.

1298

Laparoscopic surgery for colorectal cancer – Is it safe?

P.J. Guillou. *St. James Univ. Hospital, ICRF Research Unit, Leeds, UK*

Laparoscopic surgery for colorectal cancer is one of the most controversial applications of the new wave of endoscopic procedures for digestive diseases. The principal concerns revolve around the adequacy of margins of excision and the development of unusual patterns of recurrence such as port site recurrences. Despite the publication of large individual series of laparoscopic resections for colorectal cancer the issues surrounding the health care economics and patterns of recurrence have not yet been resolved. Port site recurrences have been reported to occur more frequently than do wound recurrences with conventional open surgery, but in the author's experience of over eighty laparoscopic colorectal resections there has not yet been one port site recurrence.

However, in both the authors' experience and that of others data are emerging to suggest that hospital stay is not significantly diminished by the use of laparoscopic surgery alone and other factors such as early restoration of nutrition, anaesthetic management and forced mobilisation may be more important, but if so are equally applicable to those undergoing conventional open surgery. None of these debates will be resolved by the publication of further series by individual surgeons or groups and the results of randomised clinical trials must be awaited. In the UK, the Medical Research Council's CLASICC (Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer) trial is now under way and is recruiting rapidly. The trial incorporates both pathological surrogate end points as well as clinical ones and has major quality of life and health care economic studies embedded in it. It is anticipated that this, and similar trials, will finally allow a decision to be made as to whether laparoscopic surgery for colorectal cancer is safe and cost effective.

1299

Tumour specific antigens: Perspectives for vaccination

P.G. Coulie¹, P. Van der Bruggen², B. Van den Eynde², M. Marchand², T. Boon². ¹Cellular Genetics Unit, Catholic University of Louvain, Brussels; ²Ludwig Institute for Cancer Research, Brussels, Belgium

Cytolytic T lymphocytes (CTL) that specifically lyse autologous tumour cells are often found in the blood of cancer patients. Many of the tumor antigens recognized by such CTL have been identified over the last six years. Several of them are truly tumour specific antigens and they are now being used to try to induce or to enhance tumour rejection responses in cancer patients.

There are three main classes of tumour antigens recognized by CTL: antigens encoded by genes, such as the MAGE genes, that are expressed in many tumors but that are silent in most normal tissues; differentiation antigens, such as tyrosinase, that are only expressed in normal melanocytes and in melanomas; and antigens encoded by genes that are mutated in the tumour cells. Although it seems very likely that many other tumor antigens are still to be identified, the priority is now to demonstrate that immunization against some of these antigens is clinically valuable.

A small number of patients with advanced disease received several injections of an antigenic peptide encoded by gene MAGE-3, in the absence of adjuvant. Tumour regressions were observed in 5 out of 17 melanoma tumour-bearing patients. These preliminary results might be improved by testing other modalities of immunization such as peptides or proteins combined with adjuvants, recombinant adenoviruses or poxviruses containing the genes encoding the antigens, or antigen presenting cells such as dendritic cells, incubated *in vitro* with the antigens and injected back into the patient.

1300

Vaccination against lung cancer: Animal models

Lea Eisenbach. *Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel*

Cytolytic T lymphocytes (CTL) directed against peptides presented by MHC class I molecules, constitute powerful effectors of the immune system against tumors. CTL recognizable peptide antigens have been isolated from human and murine tumors. We have isolated two Tumor Associated Antigen (TAA) peptides from a murine metastatic lung carcinoma (3LL-D122). One of the peptides, derived from a mutated connexin 37 gene (MUT1) constitutes a shared TAA between two independent lung carcinomas. Peptide vaccines based on MUT1 can cause rejection of established D122 micrometastases when the peptides are loaded on effective Antigen Presenting Cells (APCs) like the TAP deficient RMA-S cells. Syngeneic fibroblasts (BLK cells) and IL-6 transduced BLK cells loaded with MUT1 can also serve for vaccination while IL-2 transduced BLK vaccines were found to have reduced efficacy.

A second TAA peptide, He-9, was shown to be derived from an aberrant β -globin gene expressed in 3LL lines. The ability of the peptides and other K^b binding β -globin peptides to induce anti-tumor CTL versus autoimmune effects will be described.

1301

Preclinical and clinical experience with peptide-based vaccines against HPV16-induced tumors

C.J.M. Melief. *Dept. of Immunohematology and Blood Bank, University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands*

T-cell immunity occurs naturally against tumors induced by viruses and other causes. In the latter case self antigens are increasingly found to be targets of tumor associated CTL. In all categories of tumors the T cell response usually falls short of the maximally possible response. This situation calls for vaccination, primarily in situations of low tumor burden and adoptive transfer with tumor specific T cells in case of higher tumor burden. Indeed we recently observed that patients with HPV16 positive cervical carcinomas or CIN lesions only rarely show CTL responses against predicted HPV16 epitopes presented by HLA class I molecules.

In a mouse HPV16 positive tumor model we found that effective protection against HPV16⁺ tumor inocula could be achieved by vaccination with an HPV 16 E7 derived peptide in incomplete Freund adjuvant (IFA) or pulsed onto dendritic cells (DC) or with E7 protein in IFA or pulsed onto DC. In a clinical HPV16 vaccination trial 15 patients have been vaccinated with either of three escalating doses of two HLA-A*0201 binding CTL-inducing peptides and a helper peptide binding to all known HLA-DR molecules, mixed with Montanide ISA 51 adjuvant. No toxicity was associated with